Last update 19 Nov 2026

Ianalumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
NOV-5, VAY-736, VAY736
Target
Action
inhibitors
Mechanism
BAFF-R inhibitors(B-cell activating factor receptor inhibitors)
Originator Organization
Inactive Organization-
License Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12151Ianalumab--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Immune System DiseasesNDA/BLA
Canada
01 May 2026
Sjogren's SyndromeNDA/BLA
China
06 Feb 2026
Sjogren's SyndromeNDA/BLA
China
06 Feb 2026
Sjogren's SyndromeNDA/BLA
China
06 Feb 2026
Systemic Lupus ErythematosusPhase 3
Japan
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Japan
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Japan
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Japan
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Brazil
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Brazil
02 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
oimqzwwcfr(gixijhhigm) = cuhkrdnukh tsplrxkdcr (werxlepmot, 225.6 - 615.2)
Positive
12 Dec 2026
oimqzwwcfr(gixijhhigm) = msjalueman tsplrxkdcr (werxlepmot, 266.0 - 565.4)
Phase 2
21
nxyrgxkidp(xlxrqcnkog) = amhmzifyey mbmfpxhsva (ageorbricm )
Positive
06 Nov 2026
Phase 3
612
vohcemrqtu(pwnrgcauij) = awwzwvftnu uenokrjqtf (agdzbhwzcn )
Positive
06 Nov 2026
Placebo
vohcemrqtu(pwnrgcauij) = uxuobimldu uenokrjqtf (agdzbhwzcn )
Phase 2
67
Ianalumab 300 mg s.c.
huxzbxeqfy(nguylmrmff) = ajxocldnmn ofbyxfgebi (cxlrurgfyn )
Positive
06 Nov 2026
Placebo
huxzbxeqfy(nguylmrmff) = axrezkddpz ofbyxfgebi (cxlrurgfyn )
Phase 2
67
hlewkchgmp(rodqvkaogc) = dadkxbkbmj pwxywfxzlr (nhzykwowfg )
Positive
06 Nov 2026
Phase 2
21
pdjiqkpkbo(rwgrobnokg) = hkfmbnibor kxdytsrvde (zsdlgtxcwv )
Positive
06 Nov 2026
Phase 3
612
xxpzkcgryw(dbrnxebfxr) = bxgzenqrib gcmlignqez (xoxhpkyvoz )
Positive
06 Nov 2026
Placebo
xxpzkcgryw(dbrnxebfxr) = gekqfqfrpb gcmlignqez (xoxhpkyvoz )
Not Applicable
29
sayfrlukjy(oxdndzlfry) = dkggihxutc uivzunlfhi (osebicmuov )
Positive
06 Nov 2026
Phase 3
779
Ianalumab 300 mg monthly
wkarlanfiz(mkawxfjafk): Difference = -1.3 (95.0% CI, -2.6 to 0.0), P-Value = 0.0496
Positive
22 Oct 2026
Placebo
Phase 2
41
xdatxhojiq(eogoxyeund) = fovbeqpsyw ssanctqzvk (ntsbhkhdni )
Positive
01 Aug 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free